Kestra Medical Technologies (NASDAQ:KMTS) Stock: Insider Vaseem Mahboob Sells 34,809 Shares

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) CFO Vaseem Mahboob sold 34,809 shares of Kestra Medical Technologies stock in a transaction on Tuesday, October 27th. The stock was sold at an average price of $30.04, for a total transaction of $1,045,662.36. Following the completion of the transaction, the chief financial officer directly owned 60,609 shares of the company’s stock, valued at approximately $1,820,694.36. This represents a 36.48% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Vaseem Mahboob also recently made the following trade(s):

• On Wednesday, October 28th, Vaseem Mahboob sold 39,903 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $30.48, for a total transaction of $1,216,243.44.
• On Thursday, October 29th, Vaseem Mahboob sold 4,788 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $30.60, for a total transaction of $146,512.80.
• On Friday, August 7th, Vaseem Mahboob sold 26,287 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $25.88, for a total value of $680,307.56.
• On Tuesday, August 4th, Vaseem Mahboob sold 6,995 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $24.68, for a total value of $172,636.60.
• On Monday, August 3rd, Vaseem Mahboob sold 5,391 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $23.80, for a total value of $128,305.80.
• On Friday, July 31st, Vaseem Mahboob sold 8,817 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $22.61, for a total value of $199,352.37.

Kestra Medical Technologies Price Performance

Shares of KMTS opened at $29.69 on Friday. The company has a market cap of $1.77 billion, a P/E ratio of -11.12 and a beta of 0.51. The stock has a fifty day moving average price of $26.69 and a 200 day moving average price of $23.82. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.69 and a quick ratio of 4.69. Kestra Medical Technologies, Ltd. has a 12 month low of $17.34 and a 12 month high of $31.06.

Kestra Medical Technologies (NASDAQ:KMTS) last posted its earnings results on Monday, September 14th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.14). Kestra Medical Technologies had a negative net margin of 140.43% and a negative return on equity of 63.83%. The company had revenue of $30.97 million during the quarter. On average, research analysts forecast that Kestra Medical Technologies, Ltd. will post -2.45 earnings per share for the current year.

Wall Street Analysts Forecast Growth

KMTS has been the topic of a number of recent analyst reports. Oppenheimer began coverage on Kestra Medical Technologies in a report on Tuesday, July 21st. They set a “market perform” rating on the stock. BTIG Research reissued a “buy” rating and issued a $32.00 price objective on shares of Kestra Medical Technologies in a report on Tuesday, September 15th. Wolfe Research set a $30.00 target price on Kestra Medical Technologies in a research report on Wednesday, July 15th. Royal Bank Of Canada set a $30.00 target price on Kestra Medical Technologies in a research report on Tuesday, September 15th. Finally, Piper Sandler reaffirmed an “overweight” rating on shares of Kestra Medical Technologies in a research note on Tuesday, September 15th. Five investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $29.00.

Hedge Funds Weigh In On Kestra Medical Technologies

A number of institutional investors and hedge funds have recently bought and sold shares of KMTS. Corient Private Wealth LP grew its position in Kestra Medical Technologies by 284.2% in the 2nd quarter. Corient Private Wealth LP now owns 60,614 shares of the company’s stock valued at $1,542,000 after buying an additional 44,839 shares in the last quarter. Sei Investments Co. raised its position in shares of Kestra Medical Technologies by 22.6% during the 1st quarter. Sei Investments Co. now owns 237,116 shares of the company’s stock worth $4,726,000 after buying an additional 43,753 shares in the last quarter. Spartan Wealth Advisory Services LLC bought a new stake in shares of Kestra Medical Technologies during the 1st quarter worth about $603,000. Quantinno Capital Management LP bought a new stake in shares of Kestra Medical Technologies during the 1st quarter worth about $431,000. Finally, Bank of New York Mellon Corp lifted its stake in shares of Kestra Medical Technologies by 47.2% in the 1st quarter. Bank of New York Mellon Corp now owns 70,113 shares of the company’s stock worth $1,397,000 after acquiring an additional 22,471 shares during the period.

More Kestra Medical Technologies News

Here are the key news stories impacting Kestra Medical Technologies this week:

• Positive Sentiment: Kestra will participate in upcoming investor conferences, which could improve visibility for its wearable cardiac-monitoring and defibrillation platform and give management an opportunity to discuss growth plans. Kestra Medical Technologies to Participate in Upcoming Investor Conferences
• Neutral Sentiment: Analyst sentiment remains generally constructive, with five Buy ratings, two Holds and one Sell rating. Evercore initiated coverage with an Outperform rating and a $34 price target, while the reported average target is $29. However, the company remains unprofitable, and its latest quarterly loss exceeded consensus expectations.
• Negative Sentiment: Insider selling is the clearest near-term negative catalyst. CFO Vaseem Mahboob sold 79,500 shares across October 27–29 for approximately $2.41 million, reducing his direct holdings to 60,609 shares. Director Traci Umberger separately sold 30,000 shares for about $900,900. The transactions may raise concerns about insider confidence or encourage profit-taking after KMTS’s strong advance. Kestra Medical Technologies Insider Selling
• Negative Sentiment: Fundamentals remain a risk: Kestra reported a quarterly loss of $0.75 per share versus the expected $0.61 loss, with a negative net margin and analysts projecting a full-year loss of approximately $2.45 per share.

About Kestra Medical Technologies

Kestra Medical Technologies, Inc is a medical technology company focused on developing and commercializing wearable solutions for patients at risk of sudden cardiac arrest. Its primary product is the ASSURE wearable cardioverter defibrillator, a wearable device designed to continuously monitor a patient’s heart rhythm and deliver a therapeutic shock when clinically necessary.

The company’s platform combines cardiac monitoring, arrhythmia detection and defibrillation capabilities in a wearable system intended for use outside the hospital.